Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Vorinostat Maintenance After ASCT for Multiple Myeloma
NCT00839956Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 2009
- Primary completion
- Aug 2012
- Modality
- Modified Peptides, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, vorinostat in multiple myeloma (MM), sponsored by Fred Hutchinson Cancer Center. Started Feb 2009; status: completed.
02
Drugs
bortezomibvorinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00839956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00839956.